Early Vascular Healing After NeXt-generation Drug-eluting Stent Implantation in Patients with Non-ST Elevation Acute Coronary Syndrome Based on Optical Coherence Tomography Guidance and Evaluation (EXPECT): Study Protocol for a Randomized Controlled...

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2023 Mar 13

PMID 36910518

Authors

Yong-Xiang Zhu

Li Liang

Ramya Parasa

Zheng Li

Qian Li

Shang Chang

Wen-Rui Ma

Si-Li Feng

Yang Wang

Bo Xu

Christos V Bourantas

Yao-Jun Zhang

Affiliations

Soon will be listed here.

Abstract

Background: There is limited evidence about vessel wall healing response following implantation of next-generation drug-eluting stents (DES) in patients admitted with a non-ST elevation acute coronary syndrome (NSTE-ACS). Cumulative data indicate that optical coherence tomography (OCT) imaging can optimize percutaneous coronary intervention results and expedite stent endothelialization in the general population but there is lack of data in NSTE-ACS patients.

Methods: The EXPECT study is an investigator-initiated, prospective, randomized trial to assess early vascular healing response following next-generation DES implantation in patients admitted with NSTE-ACS based on OCT guidance and evaluation. Sixty patients are randomized at 1:1:1 ratio to OCT-guided percutaneous coronary intervention (PCI) with 3-month follow-up OCT imaging (O3 group, = 20), to angiography-guided PCI with 3-month follow-up OCT imaging (A3 group, = 20) and to angiography-guided PCI with 6-month follow-up OCT imaging (A6 group, = 20). The primary endpoint of the study is stent strut coverage rate at 3- or 6- month follow-up in the studied groups. The secondary endpoints of the study include OCT imaging endpoints, clinical endpoints, and molecular biology endpoints at the different time points. The clinical endpoints comprised of major cardiovascular adverse events and individual components. The molecular biology endpoints comprised of lipid levels and the levels of inflammatory indicators.

Discussion: The findings of the EXPECT study are anticipated to provide novel insights into vessel wall healing in NSTE-ACS population following implantation of next-generation DES, underscore the value of OCT imaging in expediting strut coverage in this setting, and explore the potential of an early discontinuation of dual antiplatelet therapy (DAPT) in this population.

Clinical Trial Registration: ClinicalTrials.gov, NCT04375319.

References

Wang G, Wang H, Xu B, Yang Y, Yang Z, Li H . Efficacy and safety of a biodegradable polymer Cobalt-Chromium sirolimus-eluting stent (EXCROSSAL) in treating de novo coronary artery disease: A pooled analysis of the CREDIT II and CREDIT III trials. Catheter Cardiovasc Interv. 2017; 89(S1):512-519. DOI: 10.1002/ccd.26887. View

Levine G, Bates E, Bittl J, Brindis R, Fihn S, Fleisher L . 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update.... Circulation. 2016; 134(10):e123-55. DOI: 10.1161/CIR.0000000000000404. View

Nakamura M, Iijima R, Ako J, Shinke T, Okada H, Ito Y . Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation. JACC Cardiovasc Interv. 2017; 10(12):1189-1198. DOI: 10.1016/j.jcin.2017.04.019. View

Baumbach A, Lansky A, Onuma Y, Asano T, Johnson T, Anderson R . Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of.... EuroIntervention. 2018; 14(10):1121-1128. DOI: 10.4244/EIJ-D-18-00226. View

Costa F, Windecker S, Valgimigli M . Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. Drugs. 2017; 77(16):1733-1754. DOI: 10.1007/s40265-017-0806-1. View

Lee S, Kim J, Yoon H, Hur S, Lee S, Kim J . Early Strut Coverage in Patients Receiving Drug-Eluting Stents and its Implications for Dual Antiplatelet Therapy: A Randomized Trial. JACC Cardiovasc Imaging. 2018; 11(12):1810-1819. DOI: 10.1016/j.jcmg.2017.12.014. View

Torii S, Jinnouchi H, Sakamoto A, Kutyna M, Cornelissen A, Kuntz S . Drug-eluting coronary stents: insights from preclinical and pathology studies. Nat Rev Cardiol. 2019; 17(1):37-51. DOI: 10.1038/s41569-019-0234-x. View

Wang G, Sun Z, Jin Q, Xu K, Li Y, Wang X . First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1. Catheter Cardiovasc Interv. 2015; 85 Suppl 1:744-51. DOI: 10.1002/ccd.25862. View

Taniwaki M, Windecker S, Zaugg S, Stefanini G, Baumgartner S, Zanchin T . The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. Eur Heart J. 2015; 36(32):2167-76. DOI: 10.1093/eurheartj/ehv227. View

10.

Gupta A, Shrivastava A, Vijayvergiya R, Chhikara S, Datta R, Aziz A . Optical Coherence Tomography: An Eye Into the Coronary Artery. Front Cardiovasc Med. 2022; 9:854554. PMC: 9130606. DOI: 10.3389/fcvm.2022.854554. View

11.

Russo M, Kim H, Kurihara O, Araki M, Shinohara H, Thondapu V . Characteristics of non-culprit plaques in acute coronary syndrome patients with layered culprit plaque. Eur Heart J Cardiovasc Imaging. 2019; 21(12):1421-1430. DOI: 10.1093/ehjci/jez308. View

12.

Scirica B, Bergmark B, Morrow D, Antman E, Bonaca M, Murphy S . Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2020; 75(10):1095-1106. DOI: 10.1016/j.jacc.2019.12.067. View

13.

Gu D, Qu J, Zhang H, Zheng Z . Revascularization for Coronary Artery Disease: Principle and Challenges. Adv Exp Med Biol. 2020; 1177:75-100. DOI: 10.1007/978-981-15-2517-9_3. View

14.

Taruya A, Tanaka A, Nishiguchi T, Ozaki Y, Kashiwagi M, Yamano T . Lesion characteristics and prognosis of acute coronary syndrome without angiographically significant coronary artery stenosis. Eur Heart J Cardiovasc Imaging. 2019; 21(2):202-209. DOI: 10.1093/ehjci/jez079. View

15.

Garcia-Garcia H, Muramatsu T, Nakatani S, Lee I, Holm N, Thuesen L . Serial optical frequency domain imaging in STEMI patients: the follow-up report of TROFI study. Eur Heart J Cardiovasc Imaging. 2014; 15(9):987-95. DOI: 10.1093/ehjci/jeu042. View

16.

Montone R, Niccoli G, Crea F, Jang I . Management of non-culprit coronary plaques in patients with acute coronary syndrome. Eur Heart J. 2020; 41(37):3579-3586. DOI: 10.1093/eurheartj/ehaa481. View

17.

Lee B, Kim J, Lee O, Min P, Yoon Y, Hong B . Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy. EuroIntervention. 2017; 13(16):1923-1930. DOI: 10.4244/EIJ-D-17-00792. View

18.

Cutlip D, Windecker S, Mehran R, Boam A, Cohen D, van Es G . Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17):2344-51. DOI: 10.1161/CIRCULATIONAHA.106.685313. View

19.

Yin S, Xu P, Wang B, Lu Y, Wu Q, Zhou M . Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ. 2019; 365:l2222. PMC: 6595429. DOI: 10.1136/bmj.l2222. View

20.

Suzuki S, Sotomi Y, Kobayashi T, Hamanaka Y, Nakatani S, Shiojima I . Early vessel healing after implantation of biodegradable-polymer and durable-polymer drug-eluting stent: 3-month angioscopic evaluation of the RESTORE registry. Int J Cardiovasc Imaging. 2019; 35(6):973-980. DOI: 10.1007/s10554-019-01580-2. View